CD44 and prostate carcinoma: Treatment of CD44+/CD133+ human prostate cancer stem cells isolated from populations of DU-145 and 22Rv1 cells with curcumin resulted in reduced cell-cycle progression (Ccnd1 and Cdk4) and stem-cell marker (Oct4, CD44, and CD133) gene expression [101].